Advertisement
Product › Details
Leap-In Transposase® expression technology
Next higher product group | cell culture technology_oo | |
Status | 2019-01-14 sales existent | |
Organisation | ATUM (US) | |
Group | ATUM (Group) | |
Solentim Ltd.. (1/14/19). "Press Release: Solentim and ATUM Announce Technology Collaboration to Enable Rapid, High Expression, Stable Cell Line Development". Bournemouth.
Solentim, a global leader in cell line development instrumentation, and bioengineering company ATUM, today announced a technology partnering and collaboration agreement. This agreement creates the most efficient cell line development solution for biotherapeutic drug developers yet, by integrating Solentim’s VIPS™ (verified in-situ plate seeding) hardware for isolating single cells with ATUM’s efficient Leap-In Transposase® expression technology.
“This collaboration allows Solentim and ATUM to offer a unique integrated solution to our customers and significantly accelerate stable cell line development workflows,” explains Dr Ian Taylor, Commercial Director of Solentim. “This approach means that scientists no longer need to pre-screen for high producing clones, e.g. using fluorescence detection to measure secretion from single cells or colonies. Instead, using the Leap-In Transposase technology, almost every transfected cell is a high producing clone. Combining this with high seeding efficiencies from VIPS has huge practical benefits to the workflow in time, cost and efficiency.”
“The protein pharmaceutical market is approaching a quarter of a trillion USD per year. Establishing and isolating the most suitable cell lines producing these drugs is a major manufacturing bottleneck. We are extremely excited to combine our advanced bioengineering tools with the leading instrumentation technology of Solentim to accelerate the discovery and development process” says Dr. Jeremy Minshull, CEO of ATUM.
Ends
Notes to Editors
About VIPS
VIPS™ from Solentim is a unique all-in-one instrument which performs single cell seeding into 96 well plates, verifying success by z-stack imaging the nanolitre (nL) volume droplets, and then performing whole well imaging of the single cell for the assurance of clonality regulatory requirements.
About Leap-In Transposase Technology
The Leap-In Transposase® rapidly catalyzes the stable integration of genes into a target genome. Genes are integrated as multiple independent copies with structural integrity perfectly maintained. This greatly reduces the screening burden required compared with slower, more traditional “random integration” methods where the introduced DNA is randomly fragmented and often rearranged. ATUM’s Leap-In technology is protected by over a dozen pending and issued patents.
About Solentim
Solentim enables its life science industry customers to develop a greater number of more effective pharmaceuticals to help patients live healthier, for longer. We do this through designing and manufacturing highly innovative instruments that facilitate the process of commercial cell line development. This phase of biopharmaceutical production is a high-value process which is intrinsically expensive and time-consuming. Our solutions significantly shorten the upstream cell line development workflow process and therefore make drug production faster and more cost effective. Our products, Cell Metric® and VIPS™, represent the next generation of single cell printing and provide documented proof of monoclonality for the FDA and other regulatory bodies. All of the world’s top ten pharmaceutical companies use Solentim products. Established in 2010 and with global headquarters in Dorset, UK; the organisation employs over 40 people across the UK, Europe, Asia and the USA.
About ATUM
ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fuelling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster.
For further information, contact:
Corporate Contacts:
Solentim Ltd
Ian Taylor, Sales & Marketing Director
T: +44 (0)1202 051813
E: ian.taylor@solentim.com
ATUM
Claes Gustafsson, CCO
T: +1 (650) 853 8347
E: cgustafsson@atum.bio
PR Contact:
Emma Pickup / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: solentim@sciad.com
Record changed: 2023-07-10 |
Advertisement
More documents for cell culture technology
- [1] Newcells Biotech Ltd.. (2/14/24). "Press Release: Biotech Raises further £2.35m for Lab Models that Help Avoid Animal Testing"....
- [2] FyoniBio GmbH. (2/7/24). "Press Release: FyoniBio Collaborates with BioLamina and Alder Therapeutics". Berlin....
- [3] InSphero AG. (12/14/23). "Press Release: InSphero Strengthens Its Executive Team by Appointing Paul Clémençon, MBA as Chief Business Officer". Zürich....
- [4] HeartBeat.bio AG. (11/02/23). "Press Release: HeartBeat.bio Raises € 4.5 Million in Pre-Series A Financing to Drive Development of Organoid Screening Platform for Cardiac Drug Discovery". Vienna....
- [5] Lauxera Capital Partners. (9/12/23). "Press Release: Lauxera Capital Partners Invests €17 Million in Swedish Regenerative Medicine Leader BioLamina AB". Paris & San Francisco, CA....
- [6] Sartorius AG. (8/17/23). "Press Release: Sartorius and Repligen Corporation Launch Integrated System with Biostat STR and XCell ATF for Upstream Process Intensification". Göttingen....
- [7] BioLamina AB. (8/16/23). "Press Release: BioLamina Announces Appointment of New Management Team Members"....
- [8] Sartorius AG. (8/3/23). "Press Release: Florian Funck Appointed CFO of Sartorius. New CFO to Take Over as of April 2024". Göttingen....
- [9] HUB Organoids. (7/18/23). "Press Release: HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company". Utrecht....
- [10] Merck KGaA. (7/12/23). "Press Release: Merck Invests € 23 Million to Expand Cell Culture Media Production in Kansas, USA". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top